Ondansetron controlled-release - RedHill Biopharma

Drug Profile

Ondansetron controlled-release - RedHill Biopharma

Alternative Names: BEKINDA; Bimodal release ondansetron; CDT-ondansetron; Once-daily ondansetron; RHB-102

Latest Information Update: 03 May 2017

Price : $50

At a glance

  • Originator SCOLR Pharma
  • Developer RedHill Biopharma
  • Class Antiemetics; Antipsychotics; Carbazoles; Imidazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Chemotherapy-induced nausea and vomiting; Radiotherapy-induced nausea and vomiting
  • Phase III Nausea and vomiting
  • Phase II Irritable bowel syndrome

Most Recent Events

  • 24 Apr 2017 RedHill Biopharma completes enrolment in its phase II trial for Irritable bowel syndrome in USA (PO)
  • 18 Apr 2017 RedHill BioPharma receives patent allowance for ondansetrone controlled release in USA
  • 21 Feb 2017 RedHill Biopharma completes enrolment in its phase III GUARD trial for Nausea and vomiting (in patients with acute gastroenteritis or gastritis) in USA (NCT02246439)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top